The January 2027 unblinding of the severe babesiosis study is the next binary catalyst. The company's decision to stop enrollment early (30 vs 33) without revealing interim p-values leaves uncertainty — the DSMB recommendation to complete the study is standard for a futility-boundary design. Watch for expanded-access data from patients 4 and 5 in early November 2026, which could provide an early signal on the refractory-disease approval path.
Price Chart
Executive Summary
60 Degrees Pharmaceuticals announced it will conclude enrollment in its randomized severe babesiosis study at 30 patients (vs. planned 33), with unblinding and primary endpoint results expected in January 2027. The DSMB recommended completing the originally planned enrollment but found no safety signals; the company decided to proceed to unblinding rather than wait another tick season for 3 additional patients. The company also plans to request a pre-sNDA meeting with the FDA in January 2027 to discuss a regulatory pathway for tafenoquine in babesiosis, potentially via accelerated approval using NAT-based molecular clearance as a surrogate endpoint.
Key Facts
- DSMB recommended completing the study with originally planned 33 patients; company enrolled 30 as of October 1, 2026
- Company decided to conclude enrollment at 30 and proceed to unblinding in January 2027, citing limited statistical benefit from 3 additional patients and seasonal enrollment delays
- No safety signals were identified in the study
- First 3 patients in the expanded access study achieved molecular cure (NAT-negative) after tafenoquine + atovaquone therapy
- Company plans to request a pre-sNDA meeting with FDA in January 2027 to discuss data requirements and regulatory pathway
- Company believes an approval pathway based on case reports in treatment-refractory population is possible regardless of hospital study outcome
- No FDA-approved treatment exists for human babesiosis; tafenoquine is not currently approved for babesiosis
Financial Impact
No financial figures reported in the filing; the company's forward-looking statements note substantial doubt about going-concern ability
Risk Factors
- Study may fail to meet primary endpoint at unblinding, leaving the company reliant on the more uncertain accelerated approval path
- Company has substantial doubt about going-concern basis per the forward-looking statements
- FDA may not accept NAT-based molecular clearance as a surrogate endpoint for accelerated approval
- Seasonal nature of babesiosis could delay regulatory timelines if additional enrollment needed
Investment Themes
Documents Analyzed
This report is based on 6 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001213900-26-106979 |
| Document: ea030776101ex99-1.htm | 0001213900-26-106979 |
| Document: ea030776101ex99-2.htm | 0001213900-26-106979 |
| Document: 0001213900-26-106979-index-headers.html | 0001213900-26-106979 |
| Document: 0001213900-26-106979-index.html | 0001213900-26-106979 |
| Document: 0001213900-26-106979.txt | 0001213900-26-106979 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 23, 2026 3d ago | 8-K | $0.8759 | awaiting T+5 | — | $0.8700 (−0.67%) |
Oct 6, 2026 20d ago | Press Release | $1.11 $0.9000 | ▼ −18.92% | ▼ −18.78% | $0.8700 (−21.62%) |
Oct 6, 2026 20d ago | 8-K | $1.11 $0.9000 | ▼ −18.92% | ▼ −18.78% | $0.8700 (−21.62%) |
Aug 26, 2026 8w ago | EFFECT | $1.08 $0.9495 | ▲ +12.08% | ▲ +11.96% | $0.8700 (+19.44%) |
Aug 14, 2026 10w ago | Press Release | $1.20 $1.13 | ▲ +5.44% | ▲ +4.07% | $0.8700 (+27.20%) |
Jul 30, 2026 12w ago | Press Release | $1.25 $1.15 | ▲ +8.00% | ▲ +11.62% | $0.8700 (+30.40%) |
Jul 1, 2026 16w ago | Press Release | $1.75 $1.55 | ▼ −11.43% | ▼ −11.38% | $0.8700 (−50.29%) |
May 26, 2026 21w ago | Press Release | $1.50 $1.46 | ▼ −2.67% | ▼ −3.75% | $0.8700 (−42.00%) |
May 15, 2026 23w ago | Press Release | $1.39 $1.48 | ▼ −6.47% | ▼ −5.51% | $0.8700 (+37.41%) |
Mar 31, 2026 29w ago | Press Release | $1.75 $1.81 | ▲ +3.43% | ▼ −0.52% | $0.8700 (−50.29%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers